With a price/sales ratio of 1,518.59, Scynexis Inc has a higher such ratio than 99.61% of stocks in our set.
Revenue growth over the past 12 months for Scynexis Inc comes in at -77.73%, a number that bests merely 1.7% of the US stocks we're tracking.
Scynexis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -50.63%, greater than the shareholder yield of only 8.01% of stocks in our set.
Stocks that are quantitatively similar to SCYX, based on their financial statements, market capitalization, and price volatility, are MRSN, TOCA, CBMG, ITCI, and ADAP.
SCYX's SEC filings can be seen here. And to visit Scynexis Inc's official web site, go to www.scynexis.com.
SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.
In this article we will take a look at whether hedge funds think SCYNEXIS Inc (NASDAQ:SCYX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]
SCYNEXIS, Inc. (SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Jim Maffezzoli, an experienced women’s health marketing executive, as Vice President of Marketing and Sales, effective June 1, 2020. Mr. Maffezzoli will lead marketing and commercialization of SCYNEXIS’s lead clinical asset, ibrexafungerp, pending regulatory approval, for the treatment of vulvovaginal candidiasis (VVC), more commonly known as vaginal yeast infection.
Optimism is on the rise, and investors are wondering if stocks are heading towards recovery territory. So, what does this mean for one industry that has largely outperformed the broader market amid the pandemic?Just in time for summer, J.P. Morgan strategists looked at the biotech sector’s average summertime performance over the last 19 years, versus the S&P 500, to gain insights regarding what the next few months have in store for the space. Contrary to popular belief, the biotech indexes, NBI and IBB, bested the S&P 500 during the summer season in 12 out of 19 years, including 7 of the last 10.Not to mention for the 11 years that the NBI was up going into summer, the space rounded out the year in the green 8 times. While COVID-19 could impact summer results, historically, this could b...